Title :

Efficacy of chemotherapy or chemo-anti-PD-1 combination after failed anti-PD-1 therapy for relapsed and refractory Hodgkin lymphoma: A series from Lysa centers.

Author(s) :

Rossi, Cedric [Auteur]
Gilhodes, Julia [Auteur]
Maerevoet, Marie [Auteur]
Herbaux, Charles [Auteur]
Morschhauser, Franck [Auteur]
Groupe de Recherche sur les formes Injectables et les Technologies Associées - ULR 7365 [GRITA]
Brice, Pauline [Auteur]
Garciaz, Sylvain [Auteur]
Borel, Cecile [Auteur]
Ysebaert, Loic [Auteur]
Oberic, Lucie [Auteur]
Lazarovici, Julien [Auteur]
Deau, Benedicte [Auteur]
Dupuis, Jehan [Auteur]
Chauchet, Adrien [Auteur]
Abraham, Julie [Auteur]
Bijou, Fontanet [Auteur]
Stamatoullas-Bastard, Aspasia [Auteur]
Malfuson, Jean-Valere [Auteur]
Golfier, Camille [Auteur]
Laurent, Camille [Auteur]
Pericart, Sarah [Auteur]
Traverse-Glehen, Alexandra [Auteur]
Kanoun, Salim [Auteur]
Filleron, Thomas [Auteur]
Casasnovas, Rene-Olivier [Auteur]
Ghesquieres, Herve [Auteur]

Journal title :

American journal of hematology

Abbreviated title :

Am. J. Hematol.

Publication date :

2018

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Anti-PD-1 therapy provides high response rates in Hodgkin lymphoma (HL) patients who have relapsed or are refractory (R/R) to autologous stem cell transplantation (ASCT) and brentuximab vedotin (BV), but median progression ...
Show more >Anti-PD-1 therapy provides high response rates in Hodgkin lymphoma (HL) patients who have relapsed or are refractory (R/R) to autologous stem cell transplantation (ASCT) and brentuximab vedotin (BV), but median progression free survival (PFS) is only one year. The efficacy of treatment following anti-PD-1 is not well known. We retrospectively investigated the efficacy of salvage therapies for unsatisfactory response to anti-PD-1 therapy, assessed by PET-CT according to the Lugano criteria, in 30 R/R HL patients. Patients were highly pre-treated before anti-PD-1 (70% received ASCT and 93% BV). Unsatisfactory responses to anti-PD1 therapy were progressive disease (PD) (n=24) and partial response (PR) (n=6). For the 24 PD patients, median anti-PD-1 related PFS was 7.5 months (95%CI, 5.7-11.6); 17 received subsequent CT alone (Group 1) and 7 received CT in addition to anti-PD-1 (Group 2). 16/24 patients (67%) obtained an objective response. In the 15 patients treated with the same CT, twelve obtained PR or complete response (CR). In Group 1, there were 7 CR (41%), 3 PR (18%), and 7 PD (41%). In Group 2, there were 4 CR (57%), 2 PR (29%), and 1 SD (14%). No unexpected toxicity was observed. Six patients who achieved response proceeded to allogeneic SCT. With a median follow-up of 12.1 months (7-14.7), the median PFS following the initiation of CT was 11 months (95%CI, 6.3; not reached) and the median of overall survival was not reached. These observations in highly pre-treated HL patients suggest that anti-PD-1 therapy might re-sensitize tumor cells to CT. This article is protected by copyright. All rights reserved.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

Université de Lille
CHU Lille

Collections :

• Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365

Research team(s) :

Innovation/évaluation des médicaments injectables

Submission date :

2019-02-26T17:06:54Z